Preclinical tools and services to decode B- and T-cell repertoires induced by immune responses in non-human primates
As part of its Vaccine Technology Innovations program, Médicament Québec is supporting four collaborative research initiatives bringing together academia and industry partners. Discover Dr. Estaquier’s project focused on developing preclinical tools and services to decode B- and T-cell repertoires induced by immune responses in non-human primates.
Due to their strong similarity to humans, non-human primates (NHPs) are essential for advancing our understanding of infectious diseases and developing and testing new vaccines and treatments. Interactions between T and B cells within lymphoid organs are critical to generating long-lived memory cells and producing antibodies that can control microbial infections. Gaining deeper insight into these interactions is key to understanding the dynamics of these immune cells, which form the body’s primary defense against pathogens.
Dr. Estaquier’s team will develop a tool to characterize lymphocyte populations at the single-cell level in order to decipher and monitor T- and B-cell immune responses in NHPs, using single-cell gene analysis approaches.
This multidisciplinary research activity will involve:
- A specialist in high-throughput sequencing and artificial intelligence
- A specialist in infectious disease immunology
- BD (Becton Dickinson), supporting infectious disease research through advanced equipment acquired during prior vaccine development programs
This new tool will be integrated into the development of a national infrastructure funded by the Canada Biomedical Research Fund (CBRF) and the Biosciences Research Infrastructure Fund (BRIF). By leveraging a structure dedicated to the development of innovative vaccines and therapeutic approaches, this toolkit will provide critical support to Canada’s industrial ecosystem and expand the range of available services.
This project is supported by the Government of Quebec through Médicament Québec, which is investing $0,9 million. An additional $0.4 million from industry partners brings the total investment to $1.1 million.
Comments are closed.